Value Star Asset Management Hong Kong Ltd Takes Position in Moderna, Inc. (NASDAQ:MRNA)

Value Star Asset Management Hong Kong Ltd purchased a new position in Moderna, Inc. (NASDAQ:MRNA) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 31,249 shares of the company’s stock, valued at approximately $3,107,000. Moderna makes up approximately 1.1% of Value Star Asset Management Hong Kong Ltd’s investment portfolio, making the stock its 12th biggest holding.

Several other hedge funds and other institutional investors have also made changes to their positions in MRNA. First Pacific Financial purchased a new position in Moderna during the 3rd quarter valued at approximately $27,000. Arlington Trust Co LLC grew its stake in shares of Moderna by 4,833.3% in the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after buying an additional 290 shares in the last quarter. GPS Wealth Strategies Group LLC increased its holdings in shares of Moderna by 54.1% in the 3rd quarter. GPS Wealth Strategies Group LLC now owns 513 shares of the company’s stock worth $53,000 after buying an additional 180 shares during the last quarter. Archer Investment Corp raised its position in shares of Moderna by 71.2% during the 3rd quarter. Archer Investment Corp now owns 534 shares of the company’s stock valued at $55,000 after buying an additional 222 shares in the last quarter. Finally, Parkside Financial Bank & Trust lifted its holdings in shares of Moderna by 44.9% in the 3rd quarter. Parkside Financial Bank & Trust now owns 565 shares of the company’s stock valued at $58,000 after acquiring an additional 175 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Insider Buying and Selling at Moderna

In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $109.06, for a total transaction of $1,635,900.00. Following the completion of the sale, the director now directly owns 2,101,931 shares of the company’s stock, valued at $229,236,594.86. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $109.06, for a total value of $1,635,900.00. Following the completion of the sale, the director now owns 2,101,931 shares of the company’s stock, valued at approximately $229,236,594.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Shannon Thyme Klinger sold 670 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $63,361.90. Following the transaction, the insider now owns 8,557 shares in the company, valued at approximately $809,235.49. The disclosure for this sale can be found here. Insiders have sold 124,954 shares of company stock worth $13,158,776 over the last quarter. Insiders own 15.20% of the company’s stock.

Moderna Stock Up 1.0 %

Moderna stock traded up $1.15 during midday trading on Wednesday, hitting $111.46. 3,814,197 shares of the company’s stock were exchanged, compared to its average volume of 4,046,325. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42. The firm has a 50-day moving average of $103.47 and a two-hundred day moving average of $93.79. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $142.79. The company has a market cap of $42.68 billion, a PE ratio of -8.89 and a beta of 1.62.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The company had revenue of $2.80 billion during the quarter, compared to analyst estimates of $2.53 billion. During the same quarter in the prior year, the business earned $3.61 earnings per share. Moderna’s revenue was down 44.9% on a year-over-year basis. As a group, analysts expect that Moderna, Inc. will post -7.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MRNA has been the topic of several analyst reports. Jefferies Financial Group reissued a “buy” rating and set a $125.00 price objective on shares of Moderna in a research note on Tuesday, April 9th. Oppenheimer raised shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price objective for the company in a research note on Tuesday, January 2nd. William Blair reiterated a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research note on Thursday, April 11th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $125.00 price objective on shares of Moderna in a research report on Thursday, March 28th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Moderna presently has a consensus rating of “Hold” and an average target price of $126.49.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.